Back to discover
Disease

Substance-Related Disorders

Late-stage therapeutic developmentActively researchedRising momentum
42
Publications
15
Clinical trials
6
Related conditions
1
Related treatments
12
Associated genes
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).

Research2025-03-01Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

Targeting Neuroplasticity in Substance Use Disorders: Implications for Therapeutics.

Research2024-12-17Annual review of pharmacology and toxicology

Psychedelic therapy in depression and substance use disorders.

Research2024-05-21The European journal of neuroscience

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Clinical trials

13 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
15
All trials
3
Active
7
Late-stage
6
Completed
Late-stage studies
Phase 3 · Completed · Emory University
Phase 4 · Completed · University of Illinois at Chicago
Phase 4 · Completed · Centre for Addiction and Mental Health
Phase 4 · Completed · National Institute on Drug Abuse (NIDA)
Recently completed
Phase 3 · Completed · Emory University
Phase 4 · Completed · University of Illinois at Chicago
Phase 4 · Completed · Centre for Addiction and Mental Health
Phase 4 · Completed · National Institute on Drug Abuse (NIDA)

Research activity

42 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
19782025
Most influential

Research diagnostic criteria: rationale and reliability.

Archives of general psychiatry · 1978 · 3,813 cites

Neurobiologic Advances from the Brain Disease Model of Addiction.

The New England journal of medicine · 2016 · 1,003 cites

Incentive-sensitization and addiction.

Addiction (Abingdon, England) · 2001 · 899 cites

Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On.

Annual review of psychology · 2016 · 734 cites

Extinction circuits for fear and addiction overlap in prefrontal cortex.

Learning & memory (Cold Spring Harbor, N.Y.) · 2009 · 587 cites
Recent publications
Major themes8
  • Substance-Related Disorders25
  • Hallucinogens7
  • Mental Disorders7
  • Behavior, Addictive3
  • Deep Brain Stimulation2
  • Habits2
  • Motivation2
  • Psychotherapy2
Leading journals6
  • International journal of molecular sciences3
  • Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology3
  • JAMA network open2
  • JAMA psychiatry2
  • Addiction (Abingdon, England)1
  • American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics1
Leading researchers8
  • Johnson MW2
  • Vermetten E2
  • Aboyans V1
  • Adams DR1
  • Akan M1
  • Albai O1
  • Allen H1
  • Andrieu S1
Affiliations (unnormalised)6
  • Karolinska Institutet3
  • ARQ National Psychotrauma Center2
  • Leiden University Medical Center2
  • School of Medicine2
  • School of Psychology2
  • "Federico II" University of Naples1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

Related conditions

6 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Substance-related disorders are disorders associated with substance use or abuse. The grounding frames them as a broad category that includes problematic patterns of use and addiction-related behaviors.

Causes

The grounding supports substance use or abuse as the proximate basis of the disorder category. It also indicates that addictive drugs can alter brain organization and that individual differences, psychiatric symptoms, and coping motives may contribute to vulnerability.

Pathophysiology

The literature describes addiction-related neuroadaptations in brain reward and incentive-motivation systems, including sensitization to drugs and drug-associated stimuli. It also emphasizes a shift from voluntary drug use toward compulsive drug-seeking, with involvement of prefrontal cortical inhibitory control, striatal mechanisms, extinction circuits, habits, and conditioned cues.

Risk factors

Psychiatric symptoms are described as increasing risk of dependence, and stress or negative mood can augment drug choice. The grounding also notes coping motives as a mediator of risk and highlights drug-associated Pavlovian-conditioned stimuli as contributors to drug seeking and relapse.

Current standard of care

The supplied grounding supports psychotherapy-based approaches, including motivational interviewing, as a treatment modality for substance abuse. It also indicates drug therapy as a covered area, but does not provide enough detail to specify particular medication classes.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Disorders related to substance use or abuse.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.